RPG Life Sciences Q2 Results 2026: PAT ₹28 Cr (−24.3% YoY)
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹212Cr
- +16.5% YoY
- +8.2% QoQ
- Net profit
- ₹28Cr
- −24.3% YoY
- −9.7% QoQ
- Margin
- 19%
- −2 pp YoY
- −3 pp QoQ
Guidance rank: #80 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
RPG Life Sciences Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 Adjusted EBITDA: ₹38.2 crore, margin 18.0%.
As stated in RPG Life Sciences Ltd's Q2 FY27 investor presentation · published 30 Oct 2026. Reported figures, not investment advice.
Based on RPG Life Sciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹211.6 crore, up 16.5% YoY (Q2 FY26: ₹181.7 crore) - Q2 FY27 Adjusted EBITDA: ₹38.2 crore, margin 18.0% - Q2 FY27 Adjusted PBT: ₹43.6 crore, margin 24.0% - Q2 FY Q2 FY27 Adjusted EBITDA: ₹42.5 crore, up 11.3% YoY; EBITDA margin: 20.1% (down from 21.0%) - Q2 FY27 Adjusted PAT: ₹32.3 crore, up 13.4% YoY; PAT margin: 15.3% (down from 15.7%) - Q2 FY27 Adjusted PBT
From RPG Life Sciences Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
How did RPG Life Sciences' revenue grow in the September 2026 quarter?
2 more points from RPG Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to RPG Life Sciences' margins in Q2 FY27?
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
What capex is RPG Life Sciences planning?
- API & Intermediates Expansion:
- Acquisitions: Actis Generics and Raghava Life Sciences added advanced intermediates capabilities and modern API manufacturing facilities (Page 16).
- Strategic capital commitment of ₹700 crore created with PE partner InvAscent (Page 16).
- Manufacturing Facilities Upgrades:
- Domestic Formulations plant modernization and capacity expansion in progress to boost efficiency and scalability:
- F1 Unit: capacity of 177 crore tablets and 88.5 lakh bottles annually (Page 14).
2 more points from RPG Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is RPG Life Sciences raising money or cutting debt?
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is RPG Life Sciences' order book?
See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.
RPG Life Sciences Ltd — Quarterly revenue & net profit
RPG Life Sciences Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 212 | 182 | +16.5% | 196 | +8.2% |
| Operating profit (EBITDA) | 40 | 39 | +2.6% | 44 | -9.1% |
| Operating margin | 19% | 21% | -2 pp | 22% | -3 pp |
| Profit before tax | 37 | 49 | -24.5% | 41 | -9.8% |
| Net profit (PAT) | 28 | 37 | -24.3% | 31 | -9.7% |
| EPS (₹) | 16.08 | 22.28 | -27.8% | 18.49 | -13% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What RPG Life Sciences's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were RPG Life Sciences Ltd Q2 FY27 results?
RPG Life Sciences reported net profit of ₹28 Cr (−24.3% YoY) on revenue of ₹212 Cr (+16.5% YoY) in Q2 FY27.
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 42.6 with a market cap of ₹4,968 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
API & Intermediates Expansion: - Acquisitions: Actis Generics and Raghava Life Sciences added advanced intermediates capabilities and modern API manufacturing facilities (Page 16).
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
